Leonard Zehr, Author at BioTuesdays

Developments

NeuroSense posts positive results from stage 3 ALS biomarker study

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...

June 27, 2022

Developments

Zucara Therapeutics reports positive results from Phase 1b trial in T1D

Closely-held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...

June 22, 2022

Feature

NeuroSense advancing potential paradigm shift in ALS therapy

NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...

June 21, 2022

Developments

FDA clears Rhythm Pharma’s IMCIVREE in Bardet-Biedl Syndrome

The FDA has approved Rhythm Pharmaceuticals’ (NASDAQ:RYTM) supplemental NDA for IMCIVREE (setmelanotide) for patients with Bardet-Biedl syndrome (BBS). IMCIVREE is indicated for chronic weight management in adult and...

June 17, 2022

Feature

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

QSAM Biosciences (OTCQB:QSAM) began dosing bone cancer patients in a Phase 1 study in April 2022 with its next-generation radiopharmaceutical, CycloSam, which delivers the beta-emitting radioisotope, samarium-153, to...

June 14, 2022

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Markets

BTIG starts NexImmune at buy; PT $5

BTIG initiated coverage of NexImmune (NASDAQ:NEXI) with a “buy” rating and price target of $5. The stock closed at $2.28 on May 31. NexImmune exploits signals naturally provided by dendritic cells (DCs) to activate...

May 31, 2022

Feature

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

Closely-held Iterion Therapeutics is employing a unique strategy with its lead asset, tegavivint, which is designed to bind to TBL1 (transducin beta-like protein one) and inhibit nuclear beta-catenin signaling and...

May 31, 2022

Markets

SVB cuts Avadel Pharma PT to $6 from $18

SVB Securities slashed the price target of Avadel Pharmaceuticals (NASDAQ:AVDL) to $6 from $18, but maintained an “overweight” rating, after the FDA delayed full approval of FT-218 because of a patent issue. Shares of...

May 27, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Author - Leonard Zehr

NeuroSense posts positive results from stage 3 ALS biomarker study

Zucara Therapeutics reports positive results from Phase 1b trial in T1D

NeuroSense advancing potential paradigm shift in ALS therapy

FDA clears Rhythm Pharma’s IMCIVREE in Bardet-Biedl Syndrome

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

Synlogic advancing novel biotherapeutics based on synthetic biology

BTIG starts NexImmune at buy; PT $5

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

SVB cuts Avadel Pharma PT to $6 from $18

MindMed driving therapeutic potential of psychedelics for brain health disorders

General

More